Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions다발성 경화증 파트너 내에서 다발성 경화증 환자의 SARS-CoV-2 예방 접종에 대한 면역 글로불린 G 면역 반응 기술 및 건강 솔루션 발전Article Published on 2022-06-012022-09-12 Journal: Multiple sclerosis (Houndmills, Basingstoke, Engla [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Advancing anti-CD20 blood sample Disease-modifying therapy humoral humoral immune response IgG IgG response immune immune response Immunoglobulin Immunoglobulin G management mRNA vaccine MS PATHS Multiple multiple sclerosis optimal management. partner preserved reactive receptor reduce SARS-CoV-2 SARS-CoV-2 vaccination sclerosis solution sphingosine technology tested therapy vaccination [DOI] 10.1177/13524585211061343 PMC 바로가기 [Article Type] Article
Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?Article Published on 2022-06-012023-07-09 Journal: Multiple sclerosis (Houndmills, Basingstoke, Engla [Category] COVID19(2023년), [키워드] cellular response COVID-19 Disease-modifying therapy Humoral response multiple sclerosis SARS-CoV-2 [DOI] 10.1177/13524585221089540
Prevalence, severity, outcomes, and risk factors of COVID-19 in multiple sclerosis: An observational study in the Middle EastObservational Study Published on 2022-05-012022-10-05 Journal: Journal of clinical neuroscience : official journa [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] analyses analyzed anti-CD20 therapy association Characteristics clinical risk factor clinics Comorbidity conducted coronavirus disease COVID-19 COVID-19 disease COVID-19 illness cross-sectional demographics died disease Disease-modifying therapy EDSS EDSS score evaluate evaluated full recovery higher risk hospital Hospitalization identification identify Kuwait majority median median age Middle East mild COVID-19 illness moderate Multiple multiple sclerosis multivariate analyses Odds ratio Oman outcome outcomes Patient patients with COVID-19 Prevalence Regression Regression analyses Regression analyses, odds ratio. reported risk factor severe COVID-19 severity Sex smoking therapy Treatment United Arab Emirate Univariate regression analysis [DOI] 10.1016/j.jocn.2022.02.033 PMC 바로가기 [Article Type] Observational Study
Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies질병 조절 요법으로 치료받은 다발성 경화증 환자에서 mRNA와 불활성화 백신 2회 투여 후 SARS-CoV-2 항체 반응의 비교Article Published on 2022-02-012022-09-12 Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Antibody titer BNT162b2 collected COVID-19 cross-sectional decrease Disease-modifying therapy dose greater healthy controls immune response immune system inactivated Inactivated vaccine Messenger RNA mRNA mRNA vaccine Multiple multiple sclerosis participant patients treated Pfizer/BioNTech Protective risk SARS-CoV-2 SARS-CoV-2 antibody second dose seronegative serum sample significant difference single-center Sinovac the vaccine therapy treated Treatment untreated patient Vaccine vaccine group Vaccines [DOI] 10.1016/j.msard.2022.103486 PMC 바로가기 [Article Type] Article
Clinical characteristics and outcomes of multiple sclerosis patients with COVID-19 in Toronto, CanadaCase Reports Published on 2022-02-012023-07-07 Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), [키워드] COVID-19 Disease-modifying therapy multiple sclerosis [DOI] 10.1016/j.msard.2022.103509 PMC 바로가기 [Article Type] Case Reports
Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical ViewpointCovid-19 Pandemic 동안 다발성 경화증 치료에 사용되는 약물 : 중요한 관점Article Published on 2022-01-012022-08-31 Journal: Current neuropharmacology [Category] SARS, 치료제, [키워드] Acetate activating acute respiratory distress acute respiratory distress syndrome Alemtuzumab analogue antiviral activity approved ARDS autoimmune disorder Autoimmune disorders caution cellular Cladribine concern COVID-19 COVID-19 infection COVID-19 pandemic cytokine Cytokine storm Defense depleting detrimental dimethyl fumarate disease Disease-modifying therapy drug early stage endothelial example fingolimod fumarate Glatiramer Glatiramer acetate health problem hyperinflammation Hyperinflammatory IFN IFNs immunomodulation interfere interferon Invasion lung Macrophage mechanisms Multiple multiple sclerosis Natalizumab neuroprotection Nrf-2 nucleotide nucleotides Ocrelizumab other organs overcome oxidative stress pathway potential risk Protective public health raised reinforcement respiratory distress risk risk-benefit ratio. Safe SARS-CoV-2 SARS-COV-2 infection sclerosis suggested syndrome Teriflunomide Treatment Viral viral replication [DOI] 10.2174/1570159X19666210330094017 PMC 바로가기 [Article Type] Article
Adequate antibody response to BioNTech COVID vaccine in a multiple sclerosis patient treated with siponimodLetter to the Editor Published on 2021-12-142022-10-31 Journal: The Egyptian Journal of Neurology, Psychiatry and Neurosurgery [Category] COVID-19, [키워드] Adequate anti-COVID-19 vaccination Antibody Response COVID COVID-19 Disease-modifying therapy Modulators multiple sclerosis Patient Sphingosine 1-phosphate receptor treated Vaccine [DOI] 10.1186/s41983-021-00428-8 PMC 바로가기 [Article Type] Letter to the Editor
Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients사르데냐 다발성 경화증 환자에서 BNT162b2 백신에 대한 체액 반응에 대한 다양한 질병 수정 요법의 효과Immunology Published on 2021-12-092022-09-11 Journal: Frontiers in Immunology [Category] SARS, 진단, 치료법, [키워드] Acetate addition affected age Alemtuzumab analyzed anti-SARS-CoV-2 vaccine Antibody titer Antibody titers BNT162b2 BNT162b2 vaccine Clinical data clinically COVID-19 COVID-19 vaccine demographic difference dimethyl fumarate Disease-modifying therapy drug Effect Factor fingolimod followed by fumarate Glatiramer healthy control humoral immune response Humoral immunity Humoral response immune response infected with SARS-CoV-2 interferon investigated linear Male sex mixed-effects model mRNA mRNA-based Multiple multiple sclerosis objective observé of BNT162b2 Older age Patient patients patients treated Prevent response Result Sardinian SARS-CoV-2 SARS-COV-2 infection sclerosis second dose sera serology Sex significantly significantly higher significantly lower smoking smoking status statistically significant difference Teriflunomide tested therapy Treatment treatment group treatment groups uninfected untreated patients vaccination Vaccine vaccine efficacy were assessed [DOI] 10.3389/fimmu.2021.781843 PMC 바로가기 [Article Type] Immunology
Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying TherapiesReview Published on 2021-05-192024-09-02 Journal: Current neurology and neuroscience reports [Category] 대상포진, [키워드] adverse events Disease-modifying therapy infections multiple sclerosis risk mitigation Treatment [DOI] 10.1007/s11910-021-01117-y PMC 바로가기 [Article Type] Review
Early Aggressive Treatment Approaches for Multiple Sclerosisarticle Published on 2021-05-152024-09-04 Journal: Current Treatment Options in Neurology [Category] 대상포진, [키워드] clinical trials Disease-modifying therapy High-efficacy therapies multiple sclerosis Relapsing-Remitting Multiple Sclerosis [DOI] 10.1007/s11940-021-00677-1 PMC 바로가기 [Article Type] article